A phase I study assessing Bladder-cancer-therapeutic for non-muscle invasive bladder cancer (NMIBC) patients
Latest Information Update: 06 Nov 2023
At a glance
- Drugs ZH 9 (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms PARADIGM-1
Most Recent Events
- 02 Nov 2023 According to a Prokarium media release, trial is expected to enroll in H1 2024 across multiple centers in the United States.
- 02 Nov 2023 According to a Prokarium media release, IND approval validates the innovative design of this trial paving the way for collaboration with top-tier research centers in the U.S.
- 02 Nov 2023 According to a Prokarium media release, the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for ZH9.